ATE216394T1 - Paclitaxel prodrogen, verfahren zur herstellung und ihre verwendung zur selektiven chemotherapie - Google Patents
Paclitaxel prodrogen, verfahren zur herstellung und ihre verwendung zur selektiven chemotherapieInfo
- Publication number
- ATE216394T1 ATE216394T1 AT96203571T AT96203571T ATE216394T1 AT E216394 T1 ATE216394 T1 AT E216394T1 AT 96203571 T AT96203571 T AT 96203571T AT 96203571 T AT96203571 T AT 96203571T AT E216394 T1 ATE216394 T1 AT E216394T1
- Authority
- AT
- Austria
- Prior art keywords
- paclitaxel
- beta
- prodrug
- prodrugs
- preparation
- Prior art date
Links
- HSUDWURBWSUCOB-NUDIOSPNSA-N 7-(2′,3′′-dihydroxypropyl carbonoxy)paclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-NUDIOSPNSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 3
- 108090000790 Enzymes Proteins 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 102000053187 Glucuronidase Human genes 0.000 abstract 1
- 108010060309 Glucuronidase Proteins 0.000 abstract 1
- 102000005936 beta-Galactosidase Human genes 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 1
- 102000006995 beta-Glucosidase Human genes 0.000 abstract 1
- 108010047754 beta-Glucosidase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
- C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95203671 | 1995-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216394T1 true ATE216394T1 (de) | 2002-05-15 |
Family
ID=8221031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96203571T ATE216394T1 (de) | 1995-12-29 | 1996-12-17 | Paclitaxel prodrogen, verfahren zur herstellung und ihre verwendung zur selektiven chemotherapie |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5760072A (de) |
| EP (1) | EP0781778B1 (de) |
| JP (1) | JPH09202796A (de) |
| AT (1) | ATE216394T1 (de) |
| CA (1) | CA2192424C (de) |
| DE (1) | DE69620727T2 (de) |
| DK (1) | DK0781778T3 (de) |
| ES (1) | ES2175028T3 (de) |
| PT (1) | PT781778E (de) |
| SI (1) | SI0781778T1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69734709D1 (de) * | 1996-04-15 | 2005-12-29 | Asahi Chemical Ind | Arzneimittelkomplexe enthaltend taxan-verbindungen oder steroiden |
| US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
| WO1999018113A1 (fr) * | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
| US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
| US20050222246A1 (en) * | 1999-04-14 | 2005-10-06 | Li Chiang J | Beta-lapachone is a broad spectrum anti-cancer agent |
| US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
| CA2410632A1 (en) | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| US7070797B2 (en) * | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
| US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
| KR20030033007A (ko) * | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6816571B2 (en) * | 2002-02-06 | 2004-11-09 | L-3 Communications Security And Detection Systems Corporation Delaware | Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner |
| AU2003217791A1 (en) | 2002-02-28 | 2003-09-16 | A And D Bioscience, Inc. | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof |
| WO2003079980A2 (en) * | 2002-03-19 | 2003-10-02 | A & D Bioscience, Inc. | Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
| WO2003086475A1 (en) * | 2002-04-12 | 2003-10-23 | A & D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof |
| WO2003094842A2 (en) * | 2002-05-07 | 2003-11-20 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
| AU2003244088A1 (en) * | 2002-06-20 | 2004-01-06 | Nippon Suisan Kaisha, Ltd. | Produrg, medicinal utilization thereof and process for producing the same |
| US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
| WO2006042056A2 (en) * | 2004-10-08 | 2006-04-20 | The Ohio State University | Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs |
| FR2947455B1 (fr) | 2009-07-01 | 2014-01-03 | Centre Nat Rech Scient | La dermaseptine b2 comme inhibiteur de la croissance tumorale |
| CN113952464B (zh) * | 2018-03-06 | 2024-10-15 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其应用 |
| WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| EP4175966A1 (de) * | 2020-07-06 | 2023-05-10 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Polymere mizellen mit glucuronid-prodrugs |
| CN116554214A (zh) * | 2023-05-15 | 2023-08-08 | 沈阳药科大学 | 紫杉醇-苯硼酸前药及前药纳米脂质体及制备与应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
-
1996
- 1996-09-30 US US08/722,941 patent/US5760072A/en not_active Expired - Fee Related
- 1996-12-09 CA CA002192424A patent/CA2192424C/en not_active Expired - Fee Related
- 1996-12-17 DK DK96203571T patent/DK0781778T3/da active
- 1996-12-17 ES ES96203571T patent/ES2175028T3/es not_active Expired - Lifetime
- 1996-12-17 EP EP96203571A patent/EP0781778B1/de not_active Expired - Lifetime
- 1996-12-17 SI SI9630480T patent/SI0781778T1/xx unknown
- 1996-12-17 AT AT96203571T patent/ATE216394T1/de not_active IP Right Cessation
- 1996-12-17 PT PT96203571T patent/PT781778E/pt unknown
- 1996-12-17 DE DE69620727T patent/DE69620727T2/de not_active Expired - Fee Related
- 1996-12-27 JP JP8351525A patent/JPH09202796A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2175028T3 (es) | 2002-11-16 |
| DE69620727D1 (de) | 2002-05-23 |
| SI0781778T1 (en) | 2002-10-31 |
| EP0781778A1 (de) | 1997-07-02 |
| US5760072A (en) | 1998-06-02 |
| DK0781778T3 (da) | 2002-06-17 |
| JPH09202796A (ja) | 1997-08-05 |
| CA2192424A1 (en) | 1997-06-30 |
| EP0781778B1 (de) | 2002-04-17 |
| DE69620727T2 (de) | 2002-08-22 |
| CA2192424C (en) | 2002-01-22 |
| PT781778E (pt) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69620727D1 (de) | Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie | |
| AU735243B2 (en) | Peptidyl prodrugs and methods of making and using the same | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE339225T1 (de) | Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| CY1109695T1 (el) | Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο | |
| NZ505339A (en) | Camptothecin tetracyclic derivatives useful for inhibiting topoisomerase I and/or II pyridine intermediates thereof | |
| EP0974344A3 (de) | Pharmazeutische Formulierung und Dosierform bestehend aus Polysacchariden zur kontrollierten Wirkstoff-Freisetzung im Dickdarm | |
| ATE212236T1 (de) | Durch lysosomale enzyme spaltbare antitumor- wirkstoff-konjugate | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| DE69533615D1 (de) | Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie | |
| CA2211118A1 (en) | Stable lipid-comprising drug delivery complexes and methods for their production | |
| BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| TW225532B (de) | ||
| BR0014596A (pt) | Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas | |
| AU1313095A (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role | |
| DE60022230D1 (de) | Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv | |
| WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| CA2083377A1 (en) | Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna | |
| HUT58037A (en) | Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives | |
| AU2420001A (en) | Methods and compositions for the treatment of pain | |
| EP1132383A4 (de) | Neuartige agarofuran derivate, ihre herstellung, pharmazeutische zusammensetzungen, die diese enthalten und ihre verwendung als medizin | |
| DE69031932T2 (de) | Arylsulfatase | |
| NO975371D0 (no) | Farmasöytisk sammensetning fremstilt ved tilföring av en smakstilsetningsbærer til et medikament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |